Back
Brainstorm Cell Therapeutics Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
9
BCLI
Brainstorm Cell Therapeutics
Last Price:
1.78
Seasonality Move:
11.28%
Sell
35
ALNY
Alnylam Pharmaceuticals
Last Price:
270.06
Seasonality Move:
13.19%
Sell
9
Brainstorm Cell Therapeutics (BCLI)
is a Sell
Is Brainstorm Cell Therapeutics a Buy, Sell or Hold?
- The current Brainstorm Cell Therapeutics [BCLI] share price is $1.86. The Score for BCLI is 9, which is 82% below its historic median score of 50, and infers higher risk than normal.
- BCLI is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk could be especially high.
Sell
35
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $273.91. The Score for ALNY is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
BCLI Stock Price Chart
What is Brainstorm Cell Therapeutics's stock price today?
-
The Brainstorm Cell Therapeutics share price today is $1.86
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BCLI is experiencing slight selling pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $273.91
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ALNY is experiencing buying pressure, which is a positive indicator for future bullish movement.
BCLI Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.37 | Sell |
| Relative Strength Index (14 RSI): | 30.33 | Sell |
| Chaikin Money Flow: | -9175 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (1.82 - 2.72) | Sell |
| Bollinger Bands (100): | (2.9 - 5.72) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.53 | Buy |
| Relative Strength Index (14 RSI): | 44.14 | Sell |
| Chaikin Money Flow: | 854887 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (270.99 - 291.37) | Sell |
| Bollinger Bands (100): | (223 - 289.2) | Buy |
BCLI Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.94 | Sell |
| 20-day SMA: | 2.07 | Sell |
| 50-day SMA: | 3.23 | Sell |
| 200-day SMA: | 5.54 | Sell |
| 8-day EMA: | 1.96 | Sell |
| 20-day EMA: | 2.23 | Sell |
| 50-day EMA: | 3.06 | Sell |
| 200-day EMA: | 6.33 | Sell |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 283.39 | Sell |
| 20-day SMA: | 283.12 | Sell |
| 50-day SMA: | 274.41 | Sell |
| 200-day SMA: | 205.7 | Buy |
| 8-day EMA: | 280.46 | Sell |
| 20-day EMA: | 281.6 | Sell |
| 50-day EMA: | 272.95 | Buy |
| 200-day EMA: | 226.73 | Buy |
Brainstorm Cell Therapeutics Earnings Growth & BCLI Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, an increase this year of $5.79 per share, and an increase next year of $0.67 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.86 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.48 per share, and an increase next year of $0.66 per share.
Brainstorm Cell Therapeutics Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||